4 results about "Intragastric administration" patented technology

The present application belongs to the technical field of animal model construction, and relates to a insomnia animal model construction method and application with the characteristics of body deficiency, fever and emotional irritability. The application of uncoupling agent as a modeling agent in the construction of insomnia animal model with the characteristics of body deficiency, fever and emotional irritability; the uncoupling agent is carbonic acid cyanide-4-trifluoromethoxy benzyl hydrazone, carbonyl cyanide m-chlorophenyl hydrazone or benzalazoline. The present application uses mice as model animals, uses uncoupling agent as a modeling agent, and suspends or dissolves the modeling agent, then gives the mice intragastric administration once a day, and lasts for 1-4 weeks, to construct a "deficiency and irritability insomnia" insomnia animal model with the characteristics of body deficiency, fever and emotional irritability. The present application has a high degree of consistency with the traditional Chinese medicine theory, and can be well used for the screening and evaluation of anti-insomnia chemical drugs, anti-insomnia traditional Chinese medicine compounds and anti-insomnia health care products.

The application provides a construction method and application of a polycystic ovary syndrome animal model; through a way of intragastric administration, the mouse intestinal tract is transplanted with fusobacterium nucleatum, and through a certain frequency, the fusobacterium nucleatum can be stably planted, and a stable polycystic ovary syndrome symptom is successfully generated; the sex hormone level of the mouse is significantly different from the PCOS characteristic, is shown as the increase of the LH level, the LH / FSH ratio and the T level, and multiple vesicle structures are seen in the ovary, and no mature follicle and corpus luteum are seen, so that the typical symptom of the polycystic ovary syndrome is met, and a new model selection is provided for screening of a treatment drug or experimental research of the polycystic ovary syndrome.

Compositions and methods for enhancing the absorption of therapeutic polypeptides from the intestines following oral administration The invention provides a method for increasing the systemic bioavailability of a polypeptide therapeutic agent undergoing oral, orogastric, nasogastric, or intragastric administration, said method comprising administering said polypeptide therapeutic agent together with (i) an alginate oligomer (ii) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, (I) (iii) a compound of Formula (II), or a pharmaceutically acceptable salt thereof, (II) to a portion of the intestines of a human or non-human animal subject by oral, orogastric, nasogastric, or intragastric administration, wherein said portion of the intestines is contacted with (i), (ii), (iii) and said polypeptide therapeutic agent in amounts which result in uptake of the polypeptide therapeutic agent from said portion of the intestine. Such methods allow for systemic treatment or prevention of a disease or condition or complication thereof which is responsive to, or which is prevented by, a polypeptide therapeutic agent via oral, orogastric, nasogastric, or intragastric administration routes. Further provided are compositions for use in such methods.

The application relates to the field of biological medicine, and discloses a medicine for relieving autoimmune prostatitis and application thereof, which comprises an active ingredient and a pharmaceutically acceptable sterile phosphate buffer carrier; the active ingredient is live Lactobacillus johnsonii with a number of BNCC135265 or extracellular vesicles of Lactobacillus johnsonii; the final concentration of live bacteria in the medicine is 1x10 8 to 1x10 10 CFU / mL, which is used for preparing a preparation for intragastric administration; the extracellular vesicles contain 1x10 8 to 5x10 9 particles per unit dosage form, which is used for preparing a preparation for tail vein injection administration. By using the live bacteria with the specific number or the extracellular vesicles thereof, intestinal mucosa colonization can be achieved to block endotoxin into blood, or the extracellular vesicles can be enriched in prostate lesions to inhibit a nuclear factor-kappa B inflammatory signaling pathway, reduce synthesis of proinflammatory cytokines and lymphocyte infiltration, and finally realize relief of autoimmune prostatitis.